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Abstract  
BACKGROUND: This case report intends to highlight the importance of safeguarding renal function from 
rhabdomyolysis in neuroleptic malignant syndrome (NMS) by concomitant administration of parenteral fluids at a 
high rate together with high doses of parenteral loop diuretics (we utilised 6 mg bumetanide daily) and tailed over 
a few days, in order to preserve glomerular/renal medullary perfusion and nephron function. 
CASE REPORT: This case describes an elderly lady previously diagnosed with Lewy body dementia who had 
been started on low dose quetiapine a few days previously and presented with an acute 24 – 48 hour onset of 
fever, generalised stiffness, rapidly becoming uncommunicable and with high blood pressure. Haemoglobinuria 
was present prompting intravenous treatment with labetalol to address the BP, whereas rapid isotonic saline fluid 
infusions together with intravenous high dose bumetanide were instituted to safeguard the kidneys against 
damage due to nephron deposition, both from haemoglobinuria as well as possibly myoglobin from 
rhabdomyolysis. A working diagnosis of the neuroleptic malignant syndrome with secondary malignant 
hypertension was made, and the quetiapine withdrawn. Blood pressure was after that subsequently controlled on 
amlodipine, and the haemoglobinuria quickly settled within 24 hours, with large amounts of dilute urine being 
passed on account of the forced diuresis. The fact that renal function and creatinine kinase remained normal is 
testimony to how these expedient measures averted progression to both rhabdomyolysis and renal failure in this 
case, thereby ameliorating prognosis.  
CONCLUSION: The patient was kept on infused fluids with maintenance bumetanide alone, achieving a full 
clinical recovery within the following 3 days. 
 
 
 
Introduction 
 
This case report intends to highlight the 
importance of safeguarding renal function from 
rhabdomyolysis in neuroleptic malignant syndrome 
(NMS) by concomitant administration of parenteral 
fluids at a high rate together with high doses of 
parenteral loop diuretics (we utilised 6 mg bumetanide 
daily) to preserve glomerular/renal medullary perfusion 
and nephron function, thereby encouraging a good 
urine output. It also reminds us of how blood pressure 
(BP) may rise inordinately in NMS and that in this 
situation rapid control is imperative, since high BP not 
only acts synergistically with rhabdomyolysis to cause 
renal damage but may lead to other complications, as 
in our case by setting up a microangiopathic 
intravascular haemolysis, the latter leading to 
haemoglobinuria which adds further insult to the 
nephron.  
We also need to have a very low threshold of 
suspicion for NMS in the elderly, particularly those with 
degenerative neurological disease processes, who, 
because of their low central nervous system reserve, 
remain eminently susceptible to its’ development. 
 
 
Case Report 
 
An 81-year-old lady with Lewy body dementia 
(LBD) and only on bendroflumethiazide 2.5 mg for 
well-controlled mild hypertension was admitted under 
our care, where she had been started on low dose 
quetiapine at 25 mg daily for behavioural symptoms 
one week before. Unable to volunteer any coherent 
history, she was noted to be rather apathetic, albeit 
responsive when prompted, with mild hypertonicity in 
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the left arm, in keeping with her LBD diagnosis. Four 
days later she was found febrile at 41°C, severely 
obtunded, completely and symmetrically stiff all over 
from muscular rigidity, tachycardic at 120 beats per 
minute and tachypnoeic at 33 breaths per minute. 
Other vital signs included 89% oxygen saturation on 
room air, while her blood pressure (BP) was around 
300/160 mmHg. Upon catheterisation, the urine was 
clear but had a crimson hue, resembling cranberry 
juice. Bedside dipstick urine testing with a reagent 
strip immediately registered full blood, with high 
bilirubin, moderate protein and ketones, but negative 
nitrites, no leucocytes and no glucose, while the pH 
was 6. 
Formulating a working diagnosis of the 
neuroleptic malignant syndrome (NMS) the quetiapine 
was withdrawn immediately and we set up a running 
intravenous (IV) saline infusion, after about one hour 
we administered a 6 mg bolus of bumetanide IV. The 
idea behind this forced diuresis being to allow the 
nephron to flush out any toxic products from 
erythrocyte and skeletal muscle breakdown. Such an 
intervention was intended to avert progression to renal 
failure, considering the very real possibility of 
rhabdomyolysis, compounded by the present danger 
constituted by intravascular haemolysis from 
microangiopathic haemolysis, which may be attributed 
to the acutely and inordinately elevated BP. High flow 
oxygen, was administered whereas BP was 
addressed via labetalol 50 mg by slow IV infusion. She 
was kept on IV bumetanide at 6mg daily in three 
divided doses while 0.9% isotonic saline infusion at a 
high rate (150 mLs/hour via infusion pump) was 
administered. Her urine output was monitored and 
noted to remain above 50 mLs/hour at all times. 
Table 1: Laboratory findings 
Blood index Baseline Day 1 Day 3 Reference 
range 
White cell count (x 10
9
/L) 6.4 6.7 7.5 3.5 – 11 
Haemoglobin (g/dL) 9.9 10.1 10.2 11.5 – 16.5 
Platelets (x 10
9
/L) 227 212 217 140 – 400 
Urea (mmol/L) 9.7 8.6 8.1 1.7 – 8.3 
Creatinine (µmol/L) 91 82 79 44 – 80 
Sodium (mmol/L) 141 139 138 135 – 145 
Potassium (mmol/L) 4.7 4.3 4.1 3.5 – 5.1 
eGFR (mLs/min/ 1.73 m
2
) 55 61 62  
Creatinine kinase (IU/L) 104 97 99 26 – 192 
Lactate dehydrogenase (IU/L) 476 337 269 140 – 280 
Bilirubin (μmol/L) 35 30 27 1.72 – 17.1 
Alkaline phosphatase (IU/L) 66 60 61 40 – 104 
Gamma-glutamyl transpeptidase (IU/L) 23 21 24 5 – 36 
Aspartate transaminase (IU/L) 17 19 17 5 – 40 
Alanine transaminase (IU/L) 19 22 21 10 – 35 
Haptoglobulin (mg/dL) 38 41 43 45 – 165 
 
Following the parenteral labetalol infusion, her 
BP stabilised at 160/90 mmHg, and we instituted the 
dihydropyridine calcium channel blocker amlodipine at 
5mg daily for maintenance control of blood pressure. 
The following day all parameters remained stable, her 
BP fell to 145/85 mmHg, and the IV fluids were 
decreased to a slower 12 hourly rate (84 mLs/hour); 
she continued to improve clinically, registering a full 
recovery of mental status to the premorbid baseline 
within 4 days. Subsequently, we kept her on IV 0.9% 
saline alternating with 5% dextrose for 5 more days, 
following which they were withdrawn, meanwhile, the 
bumetanide was tapered to 2 mg daily for maintenance 
treatment. 
 
 
Discussion 
 
The autonomic lability associated with NMS 
accrued an extremely high blood pressure (BP). In this 
state, damage from elevated hydrostatic pressure to 
the intima of arterioles causes fibrinoid necrosis within 
the arteriolar wall, itself triggering off the intrinsic 
coagulation cascade, which, in turn, results in the 
formation of fibrin strands, straddling the lumen like a 
cobweb. These slash and traumatise bypassing red 
blood cells (microangiopathic haemolysis) resulting in 
free haemoglobin which, following filtration through the 
glomerular sieve, impart this characteristic colour to 
the urine observed. Moreover, the serum haptoglobin 
level came back low, together with elevated lactate 
dehydrogenase (LDH), consistent with an 
intravascular haemolytic process. However, this 
resolved fairly quickly with the LDH returning to normal 
levels within 3 days. 
A pre-emptive measure to prevent acute 
nephrotoxic tubular necrosis by induction of forced 
diuresis was successful, the aim of this being to wash 
away any haemoglobin and any myoglobin crystals 
that accumulate in the nephron tubule lumen. This not 
only discourages their precipitation out of solution, 
thereby safeguarding luminal patency, but also 
reduces contact time of these toxic products with the 
basolateral tubule membrane, insofar that damage is 
minimised and a rapid re-establishment of 
physiological exchange mechanisms is promoted. 
Prognosis in NMS worsens significantly with the onset 
of renal failure. In our case, the pigmented urine 
cleared within 24 hours of starting the rapid saline 
infusion and blood pressure responded well to the 
nonspecific ɑ/ß blocker labetalol, also readily returning 
to within normal range following its administration. All 
this, together with the fact that the serum creatinine 
kinase (CK) failed to rise, are positive prognostic 
indicators that rhabdomyolysis has been effectively 
averted and bode well for a quick and full recovery. 
Autonomic instability is inherent to NMS 
insofar that both low and high blood pressure (BP) 
may occur; indeed there may also be rapid fluctuations 
in it throughout this state. However, in our case, the 
BP was sufficiently high to present an additional 
clinical adverse factor (which, if left unaddressed, may 
have led to malignant hypertension) being severe 
enough to have already initiated microangiopathic 
haemolysis (as attested by the low haptoglobin and 
isolated hyperbilirubinaemia), with subsequent 
haemoglobinuria (highly positive blood marking on the 
urine reagent strip) presenting the real possibility of 
compounding any nephron damage in the event of 
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rhabdomyolysis. Such a high BP risked causing other 
macrovascular complications such as acute stroke, 
myocardial infarction, retinal disease and acute renal 
failure. It followed that aggressive control of this added 
complication must be taken as seriously as the 
management of the NMS itself and was indeed crucial 
to ensure a positive outcome. On the other hand one 
must also be weary of low BP in NMS (in view of the 
autonomic lability) such that close BP monitoring is 
mandatory, so that drops in the BP may be countered 
with increased IV hydration to safeguard end organ 
perfusion (whilst withdrawing any BP lowering 
medication). 
 
Literature review 
Second generation antipsychotics (SGAs) or 
atypical antipsychotics have been known to result in 
correspondingly ‘atypical’ NMS where the classical 
features are altered. Traditionally NMS has been 
postulated to originate from central dopaminergic D1 
and D2 receptor blockade, leading to muscle rigidity 
and thermogenesis. In fact frequency of NMS 
incidence was found to be proportional to the potency 
of dopamine blockade in the mesocortical, mesolimbic, 
nigrostriatal and hypothalamic tracts [1]. However 
atypical antipsychotics function more via serotonergic 
5HT and adrenergic receptor blockade, bearing little or 
no central antidopaminergic activity. Quetiapine has 
been demonstrated to produce an NMS variant where 
autonomic manifestations (tachycardia, tachypnea, 
diaphoresis, BP fluctuations) seem to predominate 
over extrapyramidal symptoms (EPS); this has been 
attributed to the noradrenaline reuptake inhibition, 
histaminergic antagonism and serotonin toxicity that 
feature in quetiapine pharmacology [2] [3]. SGA 
induced NMS (SGA-NMS) has been shown to be 
somewhat more benign than the first generation 
antipsychotic (FGA) subtype, carrying a mortality of 
3% for SGA, as opposed to 16.3% for FGA induced 
NMS [4]. However, when outcomes of SGA - NMS 
were compared amongst the different individual, 
causative atypical antipsychotics, quetiapine was 
associated with the highest fatality rate at 7.7%, 
together with the lowest complete recovery rates 
(61.5%), despite carrying the least tendency towards 
EPS [5]. In this latter finding it was comparable only to 
clozapine where NMS cases occurred in the total 
absence of hypertonicity or rigidity, however, the other 
main features of NMS (fever, CK rise, autonomic 
dysfunction) remain ubiquitous amongst both FGA and 
SGA induced forms [6] [7] [8]. 
Review of case reports has demonstrated that 
SGA - NMS may occur equally with atypical 
antipsychotic monotherapy, as well as in combination 
with other psychoactive drugs [1]. Specifically, 
quetiapine has been implicated in NMS when 
combined with the likes of venlafaxine [9] [10], 
fluvoxamine [11], other antidepressants [1] and 
sulpiride [12]; paradoxically, however, quetiapine has 
also incurred NMS when associated with muscle 
relaxant drugs such as benzodiazepines and valproate 
[1]. Additionally, it has also been reported with lithium 
[1] and with antiparkinsonian drugs in a case report 
which led to a fatal outcome [13]. In this respect, the 
fact that antidepressants, lithium and other mood 
stabilisers may precipitate NMS, in combination with 
antipsychotics, led to the hypothesis that the serotonin 
excess they produce could determine a ‘relative 
hypodopaminergic state’ such that this serotonin -
dopamine disequilibrium favours NMS [14] [15]. One 
study even reports onset of NMS purely on the 
administration of an SSRI (selective serotonin 
reuptake inhibitor) combination, in the absence of 
dopamine inhibition [15]. 
The fact that quetiapine-induced NMS is 
completely idiosyncratic has been demonstrated in 
many studies, whereby it has been shown to occur 
equally with patients on steady-state doses of the drug 
without fluctuations, as well as when another 
psychoactive drug is introduced, or with dose titration 
of quetiapine [8]. Cases had occurred after patients 
had been many months stable on a fixed dose 
regimen of quetiapine, who before the onset of NMS 
had their primary psychiatric condition well controlled 
and who did not display any previous history of drug-
induced EPS [8]. Around 50% of NMS cases occurred 
with patients on stable doses of SGAs in another study 
considering all atypical antipsychotics across the 
board, whilst 60% of those cases of SGA - NMS 
(including participants on both steady state as well as 
recently altered doses of atypical antipsychotics) were 
on some other concomitant psychotropic medication 
[16]. However, certain epidemiological factors did 
emerge that effectively rendered one more susceptible 
to quetiapine-induced NMS [9] [17] [18] namely: males 
are twice more likely than females, age range of 
between 20 – 50 years and mental impairment or 
learning disability. Other pharmacological and 
pathophysiological factors were also implicated in 
increasing the likelihood of NMS with patients on 
antipsychotics in general [19] [20] [21]: history of 
previous NMS, rapid dose escalations, intramuscular 
depot antipsychotic injections (particularly upon dose 
increase), high potency neuroleptics, states of 
decreased absolute or effective circulating blood 
volumes, such as dehydration, third spacing, sepsis or 
other states of shock, and catabolic states such as 
malnutrition. 
Our case description presents underlying 
cognitive impairment as the sole risk factor; however, 
we argue that such elderly patients, particularly those 
with cognitive impairment, remain relatively more 
susceptible to the development of NMS compared with 
the general population. This challenges the commonly 
held belief that NMS occurs mostly in younger 
schizophrenic patients [22] and that presence of 
dementia seems to confer a degree of ‘immunity’ from 
the syndrome. One must bear in mind that old age 
brings about with it an increased permeability of the 
Case Report 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
4                                                                                                                                                                                                    https://www.id-press.eu/mjms/index 
 
blood-brain barrier and a lower threshold for 
neurotransmitter decompensation (lower neural mass, 
together with a decreased enzymatic degradation of 
psychoactive drugs and neurotransmitters at the 
synaptic level); additionally a lower hepatic 
metabolism rate and renal clearance rate, a lower lean 
muscle mass and increased fat to water ratio are all 
pharmacokinetic factors that potentiate the predicted 
effect of psychoactive drugs [23]. Moreover, Lewy 
body dementia is notorious for its associated 
neuroleptic sensitivity, which is potentially fatal and 
afflicts 50% of LBD patients [24]. As such we believe 
that this case is a reminder to the clinician that 
geriatric cases, particularly those with heightened 
sensitivity to neuroleptics as with LBD, remain 
eminently susceptible to not only the ‘extrapyramidal’ 
or striatonigral manifestations, but also to the other 
central manifestations of dopamine blockade, as 
resultant from neuroleptics, with the former giving rise 
to parkinsonism, whilst the latter to NMS. 
In conclusion, we wish to highlight how the 
strategy adopted above of forced diuresis with 
expedient BP control seems to be successful in 
promoting a positive outcome with NMS patients. We 
also suggest that any elderly who already have some 
form of extrapyramidal dopamine insufficiency state 
(idiopathic or drug-induced parkinsonism, LBD, 
Parkinson plus syndromes) ought to be earmarked for 
the other central dopamine deficiency complications, 
namely NMS, thereby lowering the clinicians’ 
threshold of suspicion further in such cases. 
Learning points: NMS is often subacute and 
presents insidiously a low suspicion threshold is 
needed for NMS in an elderly on antipsychotics who 
presents with psychomotor retardation or deterioration; 
cognitive impairment, particularly LBD, presents an 
additional risk factor for NMS. The usual features of 
NMS may be lacking in cases induced by atypical or 
second-generation antipsychotics (SGAs); early 
treatment is crucial in safeguarding against renal 
damage where BP must be closely monitored, and 
both excessively high or low values treated 
accordingly, since prognosis improves in cases where 
rhabdomyolysis has been averted or minimized. 
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